Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
360

Summary

Conditions
  • Chemotherapy Effect
  • Lung Cancer Squamous Cell
  • Lung Cancer Stage IV
  • PD-1 Antibody
Type
Interventional
Phase
Phase 3
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 75 years
Gender
Both males and females

Description

In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Subjects who randomized into control will have the opportunity to receive cross over treatment of SHR-1210 monotherapy after confirmed disease progression. Treatment cycles of chemotherapy wil...

In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Subjects who randomized into control will have the opportunity to receive cross over treatment of SHR-1210 monotherapy after confirmed disease progression. Treatment cycles of chemotherapy will be 4-6 which will be decided by investigators.

Tracking Information

NCT #
NCT03668496
Collaborators
Not Provided
Investigators
Study Director: Jianjun Zou, MD, PhD Jiangsu HengRui Medicine Co., Ltd. Principal Investigator: Caicun Zhou, MD, PhD Tongji University, Shanghai Pulmonary Hospital